Physician profile
Edward Leaton
NPI 1649238387
$1,335.11
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $368 · 2021: $605 · 2022: $105.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $576.71 | 2020-2022 | |
| Abbvie INC. | $227.47 | 2021-2022 | |
| Lilly USA, LLC | $191.07 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $136.44 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $47.28 | 2021 | |
| Biogen, INC. | $39.89 | 2021 | |
| Novartis Pharmaceuticals Corporation | $29.19 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $19.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2020 | |
| Amgen INC. | $19.32 | 2019 | |
| Acorda Therapeutics, INC | $16.36 | 2019 | |
| Almatica Pharma LLC | $12.08 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Leaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.